From Capital to Care: Catalyzing Innovation to Expand Access and Improve Health Outcomes
At AioT Health, our mission is grounded in clarity of purpose—here’s what drives us
WHY
We aim to compound knowledge, relationships, and capital to radically improve healthcare outcomes.
HOW
By speaking the Languages of Science, Medicine, and Venture, we build conviction and connect capital to exponential technologies for measurable, personalized impact.
WHAT
We are AioT Health—Artificial Intelligence of Things in Healthcare. A purpose-built, physician-led health technology fund, we invest in early-stage companies with visionary founders using AI and digital innovation to expand access, define categories, and create virtuous data cycles in the future of medicine.
Investment Thesis
Option 1: At AioTHealth, we believe that being directionally correct is more important than being precisely predictive in a rapidly evolving landscape. Our investment thesis is grounded in the conviction that AI is not just a standalone tool but a catalytic force that enables the convergence of deep tech domains—such as robotics, quantum computing, and synthetic biology—to redefine what’s possible in healthcare. We focus on building and backing solutions that are clinically meaningful, leveraging virtuous data cycles and exponential technologies to design the future of health.
Our strategy compounds not just capital, but also knowledge and relationships, positioning us to stay at the forefront of innovation. We seek founders and ventures who understand that long-term value creation in healthcare demands integrated thinking—where AI accelerates discovery, enhances delivery, and extends human potential across care systems. Through this lens, we invest in companies that are actively reimagining the boundaries of healthcare.
option 2: At AioT Health, we invest in visionary founders applying AI to unlock the full potential of deep tech—such as robotics, quantum computing, and synthetic biology—to build clinically meaningful, scalable healthcare solutions. We believe AI is a force multiplier that enables virtuous data cycles, personalized medicine, and system-level impact. With deep expertise across science, clinical care, and venture, we identify directionally correct opportunities where innovation compounds knowledge, relationships, and capital to radically improve access, equity, and outcomes in healthcare.
We are seeking founders using digital technologies to redefine the future of healthcare across three key domains:
Virtuous Data Cycles/Exponential Tech:
We invest in technologies that generate continuous, high-fidelity data streams—unlocking virtuous data cycles, prediction, and intervention. By harnessing AI and exponential innovation, we enable adaptive systems that personalize care and compound clinical insight over time
Cardiovascular:
Guided by our founder’s deep experience in cardiology, we seek pioneering companies using AI to reimagine the boundaries of cardiovascular health, accelerating breakthroughs in prevention, diagnosis, treatment, and recovery.
Special Situations:
Advancing breakthrough biotechnologies and biotherapeutics that leverage AI to accelerate discovery, optimize clinical development, and enable adaptive, precision-based treatment systems.
Harnessing the Power of Virtuous Data Cycles
We’re looking for founders who build with virtuous data cycles at the core
These are teams that don't just collect data—they design systems where data actively enhances the product and deepens its impact over time. A virtuous data cycle begins when customers use a product because it solves a real need. As they engage, they generate meaningful, real-world data. That data flows back into the product, enabling continuous improvement and personalization. The better the product gets, the more users it attracts—and the more high-quality data it generates
We are entering an era where innovation is accelerating healthcare at an unprecedented pace—an era where medicine is as much art as it is science. Artificial intelligence is not replacing the human touch; it’s enhancing it—elevating clinical decision-making, expanding access, and raising the floor of care. This technological transformation is propelling us toward a future of personalized medicine and better health outcomes. As powerful tools like AI, genomics, and digital health platforms converge, healthcare is being reimagined—and it demands visionary investors who can not only understand the science but also guide the art of what’s next.
The Future of Medicine is Now
Our Value Proposition
AioT Health empowers visionary founders redefining healthcare by combining deep expertise in science, medicine, and venture capital to invest in early-stage companies with transformative, data-driven potential
We bring conviction, discipline, and a bias for execution to every investment. We back founders with non-consensus insights and support them in building category-defining businesses through the compounding power of knowledge, relationships, and capital.
Our Three Key Values
Integrating process, exponential technology, and business insight helps identify impactful solutions and see beyond the hype
Understanding the Hype
Deliberately integrating knowledge, meaningful relationships, and fund returns accelerates impact at scale
Magic of Compounding
We are in the game to stay in the game and be involved in the evolution of medicine. To stay in the game, investors need returns
The Infinite Game
Principles We Follow
-
![]()
Virtuous Data Cycles
We invest in category-defining companies that create feedback loops between data, insight, and action, where each patient interaction makes the system smarter and outcomes stronger.
-
![]()
Radical Access & Outcomes
Our investment thesis is anchored in two imperatives: expanding access to care and improving outcomes. We back technologies that make healthcare more affordable, available, and effective.
-
![]()
Impact-Driven Investing
We invest in companies that address meaningful health challenges. Each portfolio company must demonstrate a clear pathway to measurable impact, aligned with the principles of the UN Sustainable Development Goals.
-
![]()
Strategic Alignment
We focus on aligning the interests of investors, entrepreneurs, clinicians, and patients to build scalable businesses that operate with integrity.
-
![]()
Principled and Methodical Investing
We value signal over noise. We evaluate ventures with clinical insight, business rigor, and a deep understanding of how exponential technologies can be translated into real-world care.
-
![]()
Sustainable Vision
We are not chasing quick wins—we are building the future of medicine. With enduring capital and commitment, we grow with the pioneers shaping tomorrow’s healthcare.
Our Portfolio
Probius is transforming diagnostics with a point-of-care platform that uses Quantum Electrochemical Spectroscopy and machine learning to detect biomarkers by their unique vibrations. Its proprietary digital twin library reveals hidden biological insights from a single sample, enabling deeper discovery and understanding.
DrugBank enables data-driven precision medicine by using natural language processing and knowledge algorithms to extract and connect clinical and molecular data. Its platform reveals drug interactions with genotypes, phenotypes, and diseases—advancing personalized treatment insights.
SeamlessMD provides a digital platform designed to modernize patient involvement in healthcare. It enhances patient engagement, tracks progress, and enables remote monitoring—seamlessly guiding patients through their care journeys across surgery, oncology, and chronic disease management.
Trexo Robotics builds gait-assist devices that help children with neurodevelopmental delays walk, often for the first time. Sensor data drives continuous improvement and future expansion into mobility solutions for the elderly.
DrugBank enables data-driven precision medicine by using natural language processing and knowledge algorithms to extract and connect clinical and molecular data. Its platform reveals drug interactions with genotypes, phenotypes, and diseases—advancing personalized treatment insights.
Alio is a wearable patch that noninvasively tracks vital signs and lab biomarkers in real time, helping prevent complications in dialysis care by wirelessly transmitting data to EMRs; the company is also expanding into defense and high-performance athletics.
Sanctuary AI has as a bold vision combining Artificial General Intelligence & Robotics to build “intelligent machines” that can perform economically valuable tasks. AioT Health invested in the Seed and Series A Rounds.
Arcascope applies algorithms to data from wearables to determine personalized circadian rhythms in order to optimize sleep-wake schedules. Arcascope is at the forefront of chronomedicine, where the impact of therapies can be improved by synchronizing with circadian rhythms.
Innovere Medical advances brain research with MRI-compatible hardware and a future software platform for exploring brain connectivity. Its flagship product, Innovision, lets patients watch streaming content during scans for a more comfortable MRI experience.
Our Personalities
-
Jehangir Appoo, MD
Founding Partner
Jehangir combines 2 decades of expertise at the front lines of health care & academia with experience in value investing to match the algorithm with the right clinical problem
-
Matt Mayer, BCom, MSc, DBA
Principal
Matt is a two-time entrepreneur with over a decade of strategic consulting experience, specializing in scaling businesses with impact-driven models
-
Ali Ardakani
Venture Partner
Ali brings over 20 years of experience in life sciences commercialization, pharmaceutical partnerships, and global mergers and acquisitions